Jnj-64251330
Adenomatous Polyposis Coli
Janssen Research & Development, LLCPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Adenomatous Polyposis Coli cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eflornithine Cancer Prevention Pharmaceuticals, Inc. | Phase 3 | BB |
Eicosapentanoic Acid S.L.A. Pharma AG | Phase 3 | BB |
Sulindac Cancer Prevention Pharmaceuticals, Inc. | Phase 3 | BB |
Azithromycin Tel-Aviv Sourasky Medical Center | Phase 4 | BB |
Dfn-15 Yonsei University | Phase 3 | BB |
View all 27 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →